Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Enveda Therapeutics Inc. (Enveda Biosciences )
Headquarters: Boulder, CO, United States of America
Website: https://www.envedabio.com/
Year Founded: 2019
Status: Private
BioCentury | Feb 28, 2025
Finance
Eikon draws $350M private round, holding off on public markets
Plus BridgeBio cancer subsidiary finds SPAC route to market, in an otherwise sleepy week for fundraising
BioCentury | Feb 28, 2025
Management Tracks
Indivior CEO exits as activist shareholder Oaktree presses for change
Plus: Paul Hitchin succeeds Laetitia Rouxel as CFO of Evotec, and updates from Elekta, Forx, Abzena and more
BioCentury | Jan 15, 2025
Management Tracks
Auspitz becomes managing partner at Curie.bio
Plus: Amphista names Paul Medeiro CBO, and updates from Apellis, Forbion, Eqt, Egle, Spero, Molecular Templates and more
BioCentury | Dec 13, 2024
Finance
Techbio VC Dimension upsizes for $500M second fund; PE firm takes stake in Andera
In BioCentury’s Venture Report: Fundings for Citryll, Angitia, Tasca, Veradermics and more
BioCentury | Aug 2, 2024
Management Tracks
James Wilson, gene therapy trailblazer, exits Penn to launch two newcos
Plus: Myriad hires Jennifer Fox as chief legal officer, and updates from Odyssey, Enveda and Accelerated Cure Project
BioCentury | Jun 14, 2024
Finance
Venture Report: Clinical plays Alzheon, Bright Peak raise growth capital
Plus: Early-stage financings for InduPro, Syntis and Moleculent; J.P. Morgan closes its life sciences vehicle; and a new fund for spinal injury
BioCentury | Apr 18, 2024
Management Tracks
Protego names Warner CEO
Plus: Foghorn hires Humer and updates from Javelin, Stoke, Sensorium, Theradaptive and more
BioCentury | Apr 20, 2023
Finance
April 20 Quick Takes: Hasten prepares for acquisitions with $315M raise
Plus: BMS, Tubulis partner and updates from BeiGene, Day One and Enveda
BioCentury | Dec 22, 2022
Regulation
Dec. 21 Quick Takes: Cash for NASH as Madrigal and Terns raise funds
Plus: FDA, EMA reviewing Pfizer’s etrasimod for ulcerative colitis and updates from ADC, AZ, CytoDyn, NGM-Merck and more
BioCentury | Oct 26, 2022
Management Tracks
With Connor leaving, GSK reorganizes roles in vaccine division
Plus Twist promotes Finn and updates from Nimbus, Enveda, X4 and more
Items per page:
1 - 10 of 10